arrow
A

Ainhoa Madariaga

instituto de investigación sanitaria hospital 12 de octubre
H指数:15
被引数:1,330

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Incremental Risk of High-Grade Adverse Events With Immune Checkpoint Inhibitors With or Without PARP Inhibitors in First-Line Treatment of Advanced Endometrial Cancer: A Systematic Review and Meta-analysis

在一线治疗晚期子宫内膜癌中使用免疫检查点抑制剂联合或单独使用PARP抑制剂导致高级别不良事件增量风险:一项系统评价和荟萃分析

2026-08-180
PRE
Multidisciplinary management of advanced ovarian cancer in Spain: expert recommendations for achieving maximum survival and improving patient care

西班牙高级别卵巢癌的多学科管理:实现最大生存率和改善患者护理的专家建议

2026-07-060
OAAI
Pragmatic gynecologic cancer clinical trials: statements and roadmap from the Gynecologic Cancer InterGroup Chicago Brainstorming Meeting

实用妇科癌症临床试验:妇科癌症协作组芝加哥头脑风暴会议的声明与路线图

2026-06-230
OAAI
Mirvetuximab soravtansine plus carboplatin in folate receptor alpha-expressing recurrent platinum-sensitive ovarian cancer

叶酸受体α表达型复发性铂敏感卵巢癌中mirvetuximab soravtansine联合卡铂的治疗效果

2026-04-230
PRE
Long-Term Young Adult Cancer Survivors with Ovarian Cancer: Subgroup Analysis of the Study “Expression VI–Carolin Meets HANNA–Holistic Analysis of Long-Term Survival with Ovarian Cancer”: The International NOGGO, ENGOT, and GCIG Survey

长期年轻成年卵巢癌幸存者:研究“Expression VI–Carolin Meets HANNA–Holistic Analysis of Long-Term Survival with Ovarian Cancer”的亚组分析:国际NOGGO、ENGOT和GCIG调查

Cancers
IF4.4
2026-04-080
OAAI
Addressing unmet needs in long-term survivors of ovarian cancer (ENGOT ov40/NOGGO S13/GEICO 71-R/Expression VI): insights from a Spanish cohort

探讨卵巢癌长期生存者中未满足需求的研究(ENGOT ov40/NOGGO S13/GEICO 71-R/Expression VI):来自西班牙队列的见解

2026-01-070
PRE
Comparing nab-Paclitaxel and Solvent-Based Paclitaxel in Platinum-Resistant Ovarian Cancer: Evidence and Perspectives

比较nab-Paclitaxel与溶剂型Paclitaxel在铂耐药性卵巢癌中的疗效:证据与展望

2025-12-110
PRE
Multidisciplinary ambulatory management of malignant bowel obstruction (MAMBO) program in patients with advanced gynecological cancers: A prospective study

妇科晚期癌症患者多学科门诊管理模式(MAMBO)在恶性肠梗阻中的应用:一项前瞻性研究

2025-10-090
PRE
Progression free survival as a surrogate of overall survival in metastatic or recurrent endometrial cancer: an EORTC Gynaecologic Cancer Group study

无进展生存期作为晚期或复发性子宫内膜癌总生存期的替代指标:一项EORTC妇科肿瘤组研究

2025-08-190
PRE